T-COVID / Altimmune - LARVOL DELTA

Altimmune Announces Financial Results for the Year Ended December 31, 2020 and Provides a Corporate Update (GlobeNewswire) - "Development of AdCOVID Vectors Targeting Emerging Variants of the SARS-CoV-2 Virus has Begun; Altimmune has commenced enrollment in its Phase 1 clinical trial of AdCOVID...Altimmune anticipates having a full data readout from this Phase 1 study in Q2 2021....Altimmune continues preclinical studies of AdCOVID...Data from these ongoing preclinical studies are expected in Q1 and Q2 2021....T-COVID: Completed Cohorts 1 and 2 in the Phase 1/2 trial of T-COVID in patients with early COVID-19....No significant safety findings have been observed to date. Cohort 3 is an efficacy and safety cohort that will include patients at higher-risk for severe COVID-19 infection...Based on these changes, data from this trial is now expected in Q2 2021."

Enrollment status • P1 data • P1/2 data • Preclinical • Trial status • Infectious Disease • Novel Coronavirus Disease

Altimmune Announces Third Quarter 2020 Financial Results and Provides a Business Update (GlobeNewswire) - "Initiated a Phase 1/2 clinical trial of T-COVID....Altimmune commenced enrollment in a Phase 1/2 clinical trial of T-COVID....The EPIC Trial (Efficacy and Safety of T-COVID in the Prevention of Clinical Worsening in COVID-19) is being funded through a $4.7 million competitive award....Based on the current rate of enrollment, Altimmune anticipates a data read-out from this study in Q1 2021."

Enrollment status • P1/2 data • Infectious Disease • Novel Coronavirus Disease

Altimmune Presents Highlights of Intranasal COVID-19 Vaccine and Therapeutic Programs – AdCOVID and T-COVID – at the World Vaccine Congress (GlobeNewswire) - "Altimmune, Inc...presented an overview of the Company’s AdCOVID and T-COVID intranasal vaccine and therapeutic candidates during a special COVID-19 virtual session of the World Vaccine Congress Washington, taking place September 28 – October 1, 2020....This year’s conference features a special COVID-19 segment dedicated to expanding knowledge to facilitate the rapid development of vaccines to address the global COVID-19 pandemic."

Clinical • Live event • Infectious Disease • Novel Coronavirus Disease

Altimmune Receives Award from U.S. Department of Defense to Fund Phase 1/2 Clinical Trial of T-COVID in Outpatients with Early COVID-19 (GlobeNewswire) - "Altimmune, Inc....today announced it was awarded $4.7 million from the U.S. Army Medical Research & Development Command (USAMRDC) to fund its Phase 1/2 clinical trial of T-COVID....The award is expected to provide Altimmune sufficient funding to cover the entire cost of conducting this clinical trial....Patient enrollment in the T-COVID Phase 1/2 trial is expected to commence in the coming weeks....If the Phase 1/2 clinical trial is successful, the Company plans to initiate a Phase 2/3 trial of T-COVID early next year....Multiple candidates of the AdCOVID vaccine are currently being evaluated at UAB....The Company intends to initiate manufacturing in July with the Phase 1 clinical trial expected to begin in Q4 of this year."

Enrollment status • Financing • New P1 trial • New P2/3 trial • Infectious Disease • Novel Coronavirus Disease

Altimmune Launches Clinical Trial of T-COVID, an Investigational Intranasal Immune Modulator for the Treatment of Patients with Early COVID-19 (GlobeNewswire, Altimmune, Inc.) - "Clearance of IND application received from the U.S. FDA; Planned Phase 1/2 outpatient clinical trial will focus on patients with early SARS-CoV-2 infection; Placebo-controlled trial expected to commence in June with data readout expected in Q4 2020; Therapeutic development program will complement Company’s single-dose intranasal COVID-19 vaccine candidate, AdCOVID; The planned clinical trial will evaluate the potential of T-COVID to prevent clinical worsening in patients with early COVID-19."

IND • New P1/2 trial • P1/2 data • Infectious Disease • Novel Coronavirus Disease